The biotech IPOs keep coming at chart-topping levels — with no slowdown in sight

Another week, another string of new biotech IPOs — and biotech IPOs pricing at record levels.

In the US, two more early-stage companies broke through the $200 million mark. The synthetic lethality-focused Repare Therapeutics upsized its IPO once from $16 to $18, to $18 to $20, and then priced at the high end to fetch $220 million. Forma Therapeutics, partnered with Bristol Myers Squibb and focused on sickle cell disease, also set at $16 to $18, sold at $20 and ultimately fetched $278 million.